Collegium to Report Third Quarter 2026 Financial Results on November 5, 2026GlobeNewsWire · 4 days ago
Collegium to Present Pediatric and Real-World Research Across ADHD Portfolio at AACAP and NEI Fall CongressesGlobeNewsWire · 5 days ago
COLL vs. DSNKY: Which Stock Is the Better Value Option?Zacks Investment Research · 6 days ago
Collegium Pharmaceutical: Under 3x Cash Earnings After A Narrow Guidance CutSeeking Alpha · Oct 17, 2026
Does Collegium Pharmaceutical (COLL) Have the Potential to Rally 111.39% as Wall Street Analysts Expect?Zacks Investment Research · Oct 16, 2026
New Strong Sell Stocks for October 7thZacks Investment Research · Oct 7, 2026Collegium Pharmaceutical, Inc. (COLL) is a specialized pharmaceutical firm dedicated to the development and marketing of medications for pain management. Its diverse product lineup features significant therapies aimed at addressing various pain conditions. A prominent offering is Xtampza ER, an extended-release, oral formulation of oxycodone, specifically engineered with properties to deter abuse.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | $1.72 | $1.92 | Beat |
| May 7, 2026 | $1.52 | $1.76 | Beat |
| Feb 26, 2026 | $2.14 | $2.04 | Miss |
| Nov 6, 2025 | $1.86 | $2.25 | Beat |
| Aug 7, 2025 | $1.62 | $1.68 | Beat |
| May 8, 2025 | $1.43 | $1.49 | Beat |